Compare Stocks

→ Putin and other countries have a plan (From Whats On Finance) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNA Allena Pharmaceuticals		$0.07	$0.06 ▼ $1.17	$37K	1.13	15.69 million shs	96,558 shs
APTO Aptose Biosciences	$1.23 -0.4%	$1.60	$1.20 ▼ $8.70	$19.26M	1.29	88,019 shs	69,080 shs
BCLI Brainstorm Cell Therapeutics	$0.52 -3.7%	$0.47	$0.13 ▼ $3.37	$35.54M	0.27	996,825 shs	144,999 shs
GMDA Gamida Cell	$0.02 -4.6%	$0.24	$0.03 ▼ $2.51	$2.55M	0.93	9.20 million shs	638,923 shs
JNCE Jounce Therapeutics	$1.88 -2.6%	$1.89	$0.58 ▼ $5.87	$98.94M	0.75	2.46 million shs	11.60 million shs

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNA Allena Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
APTO Aptose Biosciences	-0.08%	-5.38%	-20.65%	-34.75%	-83.09%
BCLI Brainstorm Cell Therapeutics	+1.52%	-1.57%	-5.25%	+68.26%	-82.29%
GMDA Gamida Cell	-4.48%	+81.59%	-95.73%	-94.72%	-98.97%
JNCE Jounce Therapeutics	0.00%	0.00%	0.00%	0.00%	-1.57%

The Hard Truth About Investing For Retirement (Ad)

Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.

Click To Access This Powerful Training Right Now!

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALNA Allena Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
APTO Aptose Biosciences	1.1406 of 5 stars	3.5	3.0	0.0	0.0	0.6	0.0	0.6
BCLI Brainstorm Cell Therapeutics	0.8983 of 5 stars	0.0	3.0	0.0	4.7	2.5	0.0	0.6
GMDA Gamida Cell	0.6076 of 5 stars	3.4	2.0	0.0	0.0	0.0	0.8	0.0
JNCE Jounce Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNA Allena Pharmaceuticals	N/A	N/A	N/A	N/A
APTO Aptose Biosciences	3.00	Buy	$19.80	1,516.33% Upside
BCLI Brainstorm Cell Therapeutics	2.00	Hold	N/A	N/A
GMDA Gamida Cell	2.75	Moderate Buy	$4.75	28,644.33% Upside
JNCE Jounce Therapeutics	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest ALNA, GMDA, JNCE, APTO, and BCLI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/3/2024	APTO Aptose Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$5.00
3/27/2024	APTO Aptose Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$23.00
2/1/2024	APTO Aptose Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$12.00 ➝ $5.00
1/29/2024	GMDA Gamida Cell	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform

(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNA Allena Pharmaceuticals	N/A	N/A	N/A	N/A	$0.23 per share	N/A
APTO Aptose Biosciences	N/A	N/A	N/A	N/A	($0.19) per share	N/A
BCLI Brainstorm Cell Therapeutics	N/A	N/A	N/A	N/A	($0.08) per share	N/A
GMDA Gamida Cell	$1.78M	1.43	N/A	N/A	($0.02) per share	-0.83
JNCE Jounce Therapeutics	$82M	1.21	N/A	N/A	$3.54 per share	0.53

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNA Allena Pharmaceuticals	-$48.66M	N/A	0.00	N/A	N/A	N/A	-287.46%	-146.58%	N/A
APTO Aptose Biosciences	-$51.21M	-$7.72	N/A	N/A	N/A	N/A	-458.70%	-205.30%	5/13/2024 (Estimated)
BCLI Brainstorm Cell Therapeutics	-$17.19M	-$0.41	N/A	N/A	N/A	N/A	N/A	-376.40%	5/20/2024 (Estimated)
GMDA Gamida Cell	-$63M	-$0.63	N/A	∞	N/A	N/A	N/A	-57.59%	5/20/2024 (Estimated)
JNCE Jounce Therapeutics	-$50.92M	-$2.56	N/A	N/A	N/A	N/A	-30.90%	-26.31%	N/A

Latest ALNA, GMDA, JNCE, APTO, and BCLI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/26/2024	Q4 2023	APTO Aptose Biosciences	-$1.48	-$1.44	+$0.04	-$1.44	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNA Allena Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
APTO Aptose Biosciences	N/A	N/A	N/A	N/A	N/A
BCLI Brainstorm Cell Therapeutics	N/A	N/A	N/A	N/A	N/A
GMDA Gamida Cell	N/A	N/A	N/A	N/A	N/A
JNCE Jounce Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNA Allena Pharmaceuticals	N/A	1.58	1.58
APTO Aptose Biosciences	N/A	0.78	0.78
BCLI Brainstorm Cell Therapeutics	N/A	0.24	0.24
GMDA Gamida Cell	213.14	2.16	2.09
JNCE Jounce Therapeutics	N/A	8.37	8.37

Ownership

Institutional Ownership

Company	Institutional Ownership
ALNA Allena Pharmaceuticals	7.33%
APTO Aptose Biosciences	26.62%
BCLI Brainstorm Cell Therapeutics	14.33%
GMDA Gamida Cell	50.34%
JNCE Jounce Therapeutics	80.66%

Insider Ownership

Company	Insider Ownership
ALNA Allena Pharmaceuticals	3.70%
APTO Aptose Biosciences	9.53%
BCLI Brainstorm Cell Therapeutics	5.45%
GMDA Gamida Cell	3.40%
JNCE Jounce Therapeutics	6.92%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNA Allena Pharmaceuticals	35	122.08 million	117.57 million	Not Optionable
APTO Aptose Biosciences	31	15.72 million	14.22 million	No Data
BCLI Brainstorm Cell Therapeutics	29	68.34 million	64.62 million	Optionable
GMDA Gamida Cell	143	154.05 million	143.70 million	Optionable
JNCE Jounce Therapeutics	137	52.63 million	48.99 million	Optionable

ALNA, GMDA, JNCE, APTO, and BCLI Headlines

Source	Headline
	Jounce Therapeutics gets grant for monoclonal antibody for treating cancer by binding PD-1 pharmaceutical-technology.com - April 15 at 12:47 PM
	Multimatic Jounce Control Dampers Now Available For Chevy Colorado ZR2 gmauthority.com - April 13 at 9:57 AM
	2024 Jeep Gladiator Mojave Keeps On Truckin' caranddriver.com - April 8 at 7:30 PM
	San Diego VC, OrbiMed make competing buyout offers for struggling Theseus bizjournals.com - November 27 at 12:12 PM
	Jounce Media Designates Yahoo Backstage as the Open Web's Largest MFA-Free Supply Source tmcnet.com - September 19 at 2:48 PM
	Kargo Is Industry’s Only Scaled 100% Premium SSP According To Jounce Media finance.yahoo.com - September 18 at 2:58 PM
	Mediavine Represents the Largest Percentage of DEI-owned Websites, Per Data from Jounce Media tmcnet.com - September 5 at 5:55 PM
	Board Member at Jounce Therapeutics Exercises Options Worth $324K benzinga.com - May 5 at 3:51 PM
	Board Member at Jounce Therapeutics Exercises Options Worth $172K benzinga.com - May 4 at 7:17 PM
	Jounce Therapeutics Director Acquires 51,400 Shares After Exercising Company Stock Options benzinga.com - May 4 at 2:17 PM
	Jounce Therapeutics Board Member Acquires 1,883,269 Shares After Exercising Company Stock Options benzinga.com - May 4 at 2:17 PM
	Jounce Therapeutics Announces Closing of Tender Offer finance.yahoo.com - May 3 at 11:14 PM
	JNCE Jounce Therapeutics, Inc. seekingalpha.com - April 29 at 2:33 AM
	The past five years for Jounce Therapeutics (NASDAQ:JNCE) investors has not been profitable finance.yahoo.com - April 17 at 1:51 PM
	What is Wall Street's Target Price for Jounce Therapeutics Inc (JNCE) Stock Monday? benzinga.com - March 29 at 6:43 PM
	JNCE STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Jounce Therapeutics, Inc. Is Fair to Shareholders markets.buffalonews.com - March 27 at 5:48 PM
	Buyout Offer Sends Jounce Jumping 20% msn.com - March 27 at 5:48 PM
	Jounce Therapeutics Shares Rally on Buyout Deal >JNCE marketwatch.com - March 27 at 12:47 PM
	Jounce Therapeutics Agrees to Buyout, Drops Redx Deal >JNCE marketwatch.com - March 27 at 12:47 PM
	Jounce dumps Redx Pharma for acquisition by Concentra; to cut 84% of jobs finance.yahoo.com - March 27 at 12:47 PM
	Moore Kuehn Encourages JNCE, USX, INDT, and BHWB Investors to Contact Law Firm benzinga.com - March 23 at 9:08 PM
	Tang Capital Partners Now Owns 10.2% of Jounce Therapeutics 247wallst.com - March 17 at 7:18 PM
	Jounce Therapeutics Announces Results from Pre-Planned Data Review of INNATE Phase 2 Trial of JTX-8064 and Pimivalimab Demonstrating Deep and Durable Responses in Platinum Resistant Ovarian Cancer finance.yahoo.com - March 16 at 7:06 PM
	Jounce (JNCE) Up 41% on Buyout Offer From Concentra Biosciences finance.yahoo.com - March 16 at 2:06 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Allena Pharmaceuticals

NASDAQ:ALNA

Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.

Aptose Biosciences

NASDAQ:APTO

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Brainstorm Cell Therapeutics

NASDAQ:BCLI

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

Gamida Cell

NASDAQ:GMDA

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with hematologic malignancies, as well as in Phase II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, an investigational NK cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was incorporated in 1998 and is headquartered in Jerusalem, Israel.

Jounce Therapeutics

NASDAQ:JNCE

Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial